Evidence map›Paper›PMID 20945821›Full record

Trial reportJournal of medicine and life

Cerebrolysin adjuvant treatment in Broca's aphasics following first acute ischemic stroke of the left middle cerebral artery.

Dragos Catalin Jianu, Dafin Fior Muresanu, Ovidiu Bajenaru, Bogdan Ovidiu Popescu, Sanda Maria Deme, Herbert Moessler, Sibilla Zimmermann Meinzingen, Ligia Petrica, Ligia Petria

Erratum issuedOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC
In one paragraph

Trial report in Journal of medicine and life. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2020
    Pooled it
  2. Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Pooled it
  4. Cerebrolysin for acute ischaemic stroke.The Cochrane database of systematic reviews · 2016
    Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

  • Erratum issued
    Petria, Ligia [corrected to Petrica, Ligia]
5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dragos Catalin JianuDepartment of Neurology, [corrected] Victor Babes University of Medicine and Pharmacy, Clinical Emergency County Hospital, [corrected] Timisoara, Romania. dcjianu@yahoo.com
Dafin Fior Muresanu
Ovidiu Bajenaru
Bogdan Ovidiu Popescu
Sanda Maria Deme
Herbert Moessler
Sibilla Zimmermann Meinzingen
Ligia Petrica
Ligia Petria
Victor Babeș University of Medicine and Pharmacy Timișoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of our study was to assess the efficacy of Cerebrolysin administration in Broca's aphasics with acute ischemic stroke.

methodsWe registered 2212 consecutive Broca's aphasics following an acute ischemic stroke admitted in four departments of neurology in Romania, between September 2005 and September 2009. Language was evaluated with the Romanian version of the Western Aphasia Battery (WAB). The following inclusion criteria were used for this study: age 20-75 years, admission in the hospital within 12 hours from the onset of the symptoms, diagnosis of first acute left middle cerebral artery (MCA) ischemic stroke, presence of large artery disease (LAD) stroke, a NIHSS score of 5-22 points, and a therapeutic time window within 72 h. Fifty two patients were treated with Cerebrolysin (Cerebrolysin group) as an adjunctive treatment. A placebo group, which received saline infusions (n=104 patients) were matched to the NIHSS and WAB scores, gender and age of the Cerebrolysin group at baseline. We assessed spontaneous speech (SS), comprehension (C), repetition (R), naming (N), and Aphasia Quotient (AQ) scores of the two groups in an open label design, over 90 days, the mRS scores and mortality.

resultsThe Cerebrolysin and the placebo groups had similar age (66 +/- 8 versus 65 +/- 8 years) and sex ratio (14/38 versus 30/74). The mean AQ scores and the mean subscores for 3 subtests of WAB (SS, R, N) were similar at baseline and improved in the Cerebrolysin group significantly (p < 0.05) over placebo group at all study time points. The mRS score at 90 days was also lower in the Cerebrolysin group than in the placebo group. Cerebrolysin and placebo were both tolerated and safe, and no difference in the mortality rate was seen (3.8% in each group).

conclusionCerebrolysin is effective for the treatment of Broca's aphasics with a first acute ischemic stroke of the left MCA territory.

Indexed as

AdultAgedAmino AcidsAphasia, BrocaChemotherapy, AdjuvantFemaleHumansInfarction, Middle Cerebral ArteryMagnetic Resonance ImagingMaleMiddle AgedNeuroprotective AgentsRomaniaYoung AdultAmino AcidscerebrolysinNeuroprotective Agents

Identifiers

PMID20945821
PMCPMC3019000
OpenAlexW1593635982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.